Clinical TrialsSearch results
Number of results: 916
Completed
- A mass-balance study of [14C]KDT-3594 in healthy adult male
- Healthy condition
- Shimizu Yoshitaka
- 2022-10-16
Completed
- A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD Subjects
- Chronic Kidney Disease /Type 2 Diabetes Mellitus
- Myoishi Masashi
- 2021-09-14
Completed
- A Ph2, randomized, double-blind, dose finding study to describe the immunogenicity, safety and tolerability of VN-0200 in Japanese adults aged 60-80 years
- Prevention of respiratory syncytial viral infection
- Inoguchi Akihiro
- 2022-09-08
Completed
- A pharmacokinetic study of NPC-15 Tablet (for adult use)
- Sleep-onset difficulty associated with mild cognitive impairment or dementia
- Eto Takashi
- 2023-03-02
Completed
- A Phase 1 Clinical Trial of EB-1020 in Healthy Subjects (Single and Multiple Ascending Doses)
- Attention deficit hyperactivity disorder (ADHD)
- Sanada Nobuhito
- 2022-07-25
Completed
- A Phase 1 Mass Balance Study of Oral [14C] TAS-115 in Healthy Adult Male Subjects
- Chronic fibrosing interstitial lung diseases with a progressive phenotype
- Huang Jinhong
- 2021-09-07
Completed
- A phase 1 open-label study evaluating the effects of food on TAS-205 in healthy volunteers
- Duchenne Muscular Dystrophy
- Takeda Shin'ichi
- 2023-06-25
Completed
- A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Axatilimab When Administered by Intravenous Infusion to Healthy Japanese Participants
- GVHD, healthy voluteer
- Ono Shintaro
- 2023-02-27
Completed
- A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Japanese Participants
- Inflammatory disease
- On Shintaro
- 2021-10-18
Completed
- A Phase 1, open label study to evaluate the pharmacokinetics, safety and tolerability of single subcutaneous dose amlitelimab in healthy adult participants.
- Healthy adult participants
- Tanaka Tomoyuki
- 2022-08-31